JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL.
McKenney AS, et al. Among authors: rampal r.
J Clin Invest. 2018 Oct 1;128(10):4743. doi: 10.1172/JCI124920. Epub 2018 Sep 17.
J Clin Invest. 2018.
PMID: 30222137
Free PMC article.
No abstract available.